{"title":"Gender and smoking – does it matter for lung function in sarcoidosis? An analysis of large cohort (n=1260) Caucasian patients.","authors":"P. Boros, M. Martusewicz-Boros, S. Wesołowski","doi":"10.1183/13993003.congress-2018.pa3000","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa3000","url":null,"abstract":"Rationale: Sarcoidosis is classified as interstitial lung disease (ILD) and potentially restrictive, however airway obstruction is more common when compared to other ILDs. Smoking habit is well known independent risk factor for airway obstruction. Sex differences in disease presentation were observed in sarcoidosis. The prevalence of lung function disturbances is dependent on predicted used. The aim of study was to check if the smoking habit and gender have impact of lung function tests in the large group of sarcoidosis patients when the most recent spirometric predicted are in use. Material and Methods: Lung function data (spirometry, static lung compliance - CL, st, and single breath transfer factor - TL, CO) of 1260 consecutive patients with sarcoidosis (633 f, 627 m) were analyzed using most recent predicted GLI-2012. Results: We identified 25% patients with spirometry detectable disturbances. Airflow obstruction was detected in 142 (11.3%) and restrictive pattern in 114 (9%) of them. Lung function indices attributed to parenchymal involvement (TL, CO, CL, st) were affected in 45%. We identified 487 patients (38% of all) as ever-smokers, who had significantly lower FEV1, FVC and TL, CO but not FEV1/FVC ratio values. Multivariate analysis revealed that more advanced stage of the disease is the most important risk factor for abnormalities in lung function, while smoking independently to gender affects TL, CO. Conclusion: Sex differences seems to not have any influence on lung function while smoking affects TL, CO results but not spirometry, particularly signs of airway obstruction, in sarcoidosis patients.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125373286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Kotsiou, Z. Daniil, Eugenios Bouzetos, Helen Panagiotidou, Maria Fouka, F. Malli, Fotini Bardaka, K. Antoniou, Anna-Maria Psara, Z. Mamuris, K. Gourgoulianis, E. Zifa
{"title":"Late Breaking Abstract - Reduced activity of energy-transducing NADH-quinone oxidoreductase (complex I) indicates mitochondrial respiratory chain dysfunction in patients with sarcoidosis","authors":"O. Kotsiou, Z. Daniil, Eugenios Bouzetos, Helen Panagiotidou, Maria Fouka, F. Malli, Fotini Bardaka, K. Antoniou, Anna-Maria Psara, Z. Mamuris, K. Gourgoulianis, E. Zifa","doi":"10.1183/13993003.congress-2018.pa2997","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa2997","url":null,"abstract":"","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"348 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131397681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dynamics of the incidence and primary disability of sarcoidosis in Belarus","authors":"H. Baradzina","doi":"10.1183/13993003.CONGRESS-2018.PA3013","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA3013","url":null,"abstract":"","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122221301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
U. Zinchenko, A. Starshinova, M. Filatov, V. Burdakov, S. Landa, N. Denisova, P. Yablonskiy
{"title":"Evaluation of specific immune complexes in patients with pulmonary sarcoidosis.","authors":"U. Zinchenko, A. Starshinova, M. Filatov, V. Burdakov, S. Landa, N. Denisova, P. Yablonskiy","doi":"10.1183/13993003.congress-2018.pa3011","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa3011","url":null,"abstract":"","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"153 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115120192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Merenkova, Y. Dziublyk, G. Gumeniuk, M. Gumeniuk
{"title":"Glucocorticosteroid therapy as predisposing factor for pulmonary sarcoidosis relapse","authors":"I. Merenkova, Y. Dziublyk, G. Gumeniuk, M. Gumeniuk","doi":"10.1183/13993003.congress-2018.pa3006","DOIUrl":"https://doi.org/10.1183/13993003.congress-2018.pa3006","url":null,"abstract":"Сorticosteroids (CS) remain the mainstay of therapy in sarcoidosis. Their effectiveness has been proved in many clinical trials. At the same time, the higher rate of relapses has been registered in patients, treated with CS, comparing with those, who didn’t receive corticosteroid therapy. Aim: to study the rate of relapses of pulmonary sarcoidosis in patients with asymptomatic debut of the disease upon completion of CS therapy. Methods: We examined 46 patients with stage II sarcoidosis without clinical manifestations of the disease and normal lung function. All patients underwent clinical examination, chest CT-scan. The patients were distributed in two groups: Group 1 received no therapy at visit 1 after the diagnosis has been made. In three months at visit 2 the patients with spontaneous regression based on CT data continued to be under observation (subgroup A). In patients with the CT signs of no improvement or progression at visit 2 (subgroup B) a CS treatment was initiated. Group 2 received standard CS therapy starting from visit 1. Results: The relapses of sarcoidosis based on CT data were revealed in 10 (21,7 %) patients – all with 1 year upon therapy completion (in 6 months – 7, in 12 months – 3). There were 4 ((12,1 ± 5,6) %) relapses in patients of group 1: subgroup A – 1 case (4,6 %); subgroup B – 3 cases (27,3 %). In group 2 the relapses occurred much more often – in 6 cases ((46,1 ± 13,8) %). Conclusion: CS therapy is a risk factor for sarcoidosis relapse. Therefore, despite their high efficacy, corticosteroids are recommended in asymptomatic patients only in cases of progressive disease or lack of improvement after 3 months follow-up period.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114690614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Sabadash, S. Skornyakov, I. Medvinskiy, E. Egorov, E. Filatova, Maria Peretrukhina, M. Chernenko, E. Ivanchikova, Ilia Diachkov
{"title":"Optical coherence tomography in the diagnosis of sarcoidosis of lung and other organs","authors":"E. Sabadash, S. Skornyakov, I. Medvinskiy, E. Egorov, E. Filatova, Maria Peretrukhina, M. Chernenko, E. Ivanchikova, Ilia Diachkov","doi":"10.1183/13993003.CONGRESS-2018.PA5213","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA5213","url":null,"abstract":"Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomas. The disease can affect the lungs, skin, lymph nodes, eyes, liver, heart, and brain. As for the eyes it occupies 3-4 place among organs-target. Diagnosis of eye sarcoidosis is quite complicated and is usually found in ophthalmologic examination. Objective: Studying of diagnostic significance of additional methods of ophthalmology examination for sarcoidosis of lung and other localizations. Methods: It was a prospective investigation. The study group consisted of patients with the first identified sarcoidosis in different organs. The control group consisted of patients with tuberculosis (TB) with various localizations. It was interrogated patients by special questionnaire, and then it was done conventional ophthalmology examination and optical coherence tomography (iVue-100v3.2, Optovue, USA). Results: The study group. First identified sarcoidosis: interthoracic lyphnodes was 66, 8% of cases, interthoracic lyphnodes and lung - 22, 2%, lung - 5, 5% and first identified general sarcoidosis (3 and more localizations) - 5, 5%. Retinal lesions: macular degeneration was 33, 3% of cases, macular retinal edema – 11, 1%, retinal detachment – 17, 6%, epiretinal membrane – 5, 6%, healthy retina – 33, 3%. The control group. TB of lung was 89% of cases, TB of bones - 5, 5% and combined TB lesions - 5, 5%. It was not detected any morphological retinal lesions by optical coherence tomography. Conclusions: Degenerative-dystrophic eye processes for sarcoidosis can be diagnosed by optical coherence tomography. This makes it possible to identify specific eye lesions in the early stages.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122819696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Baranova, M. Ilkovich, A. Speranskaya, V. Perlei
{"title":"Advanced pulmonary sarcoidosis: long-term follow-up of 10 years or more","authors":"O. Baranova, M. Ilkovich, A. Speranskaya, V. Perlei","doi":"10.1183/13993003.CONGRESS-2018.PA5209","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA5209","url":null,"abstract":"","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"44 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132089862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Placebo-controlled randomised trial of dexamethasone for quality of life in pulmonary sarcoidosis","authors":"R. Vis, E. Garde, I. Korenromp, J. Grutters","doi":"10.1183/13993003.CONGRESS-2018.PA5206","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA5206","url":null,"abstract":"Many patients with pulmonary sarcoidosis experience reduced quality of life. Although oral corticosteroids are the most common agents used in sarcoidosis, very little is known on the effects on quality of life. We evaluated the efficacy of low dose oral dexamethasone in newly diagnosed patients without an indication for high dose immunosuppressive therapy. In this double-blind, placebo-controlled trial, patients were randomised to once-daily dexamethasone 1 mg (6.5 mg prednisone equivalent) or placebo for 6 months. The primary study parameter was the subscale physical functioning of the 36-item Short Form health survey (SF-36). Secondary parameters included other patient reported outcome measures, disease activity markers and plasma cytokine profiles. A total of 16 patients were randomised to dexamethasone (n=7) and placebo (n=9). During follow-up no significant difference for physical functioning was measured (p=0.184). Dexamethasone treated patients showed a decrease in fatigue score (Checklist Individual Strength) from 106 (baseline) to 88 (3 months; p=0.032); 86 (6 months; p=0.048); 90 (12 months; p=0.025). Placebo treated patients showed no change: 96 (baseline) to 105 (3 months; p=0.163); 91 (6 months; p=0.483); 95 (12 months; p=0.904). During treatment with dexamethasone significant improvements in the SF-36 subscales vitality and pain, and a reduction in serum cortisol, angiotensin-converting enzyme and soluble interleukin 2 receptor levels were measured. Low-dose dexamethasone results in a reduction of the inflammatory profile and has the potential to improve quality of life parameters and fatigue.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127367776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Freitag-Wolf, J. Schupp, A. Fischer, V. Mihailović-Vučinić, P. Rottoli, A. Prasse, S. Schreiber, M. Krawczak, J. Müller‐Quernheim
{"title":"Genetic Profiles of Clinical Features in Sarcoidosis","authors":"S. Freitag-Wolf, J. Schupp, A. Fischer, V. Mihailović-Vučinić, P. Rottoli, A. Prasse, S. Schreiber, M. Krawczak, J. Müller‐Quernheim","doi":"10.1183/13993003.CONGRESS-2018.OA2160","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.OA2160","url":null,"abstract":"Introduction: Sarcoidosis is characterized by a distinct clinically heterogeneity, regarding the type of onset, the involved organs and the course of the disease, and by a strong genetic background. Genome-wide association studies have so far identified several genetic risk factor associated with sarcoidosis. We therefore hypothesized that these know risk factor for sarcoidosis might also associate with certain clinical features of the disease. Methods: We analyzed 1909 European Caucasian patients with sarcoidosis of the GenPhenReSa cohort, who were phenotyped at 31 study centres, and had sufficient overlapping clinical and genetic data. SNPs of 137 candidate genes with known association to sarcoidosis were genotyped in extracted DNA by SequenomMass-Array iPlex or Taqman technology. Logistic regression models were applied in order to identify SNPs which significantly distinguish sarcoidosis patients with different clinical states. Age at diagnosis, geographical origin, gender, and smoking history were used as covariates in the linear model in order to control for known confounders. Results: We could reproduce highly significant associations of the SNPs rs1800629 (Locus of TNF), rs4143332 (HLA-B), and rs9271366 (HLA-DRB1) with the type of onset (acute vs. subacute) in sarcoidosis. As a new finding, we observed that SNP rs1800629 (TNF) associates with a complicated course of the disease, defined as need for several periods of immunosuppressive treatment or long-lasting treatment (>1year). Conclusions: In the hitherto tested variables, we found that the GenPhenReSa cohort is suitable for genetic analysis of European Caucasians. We could show that genetic risk factor associate with distinct clinical features in sarcoidosis.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123374339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Differential expression of ubiquitin and PU.1 in granulomatous lesions of tuberculosis and sarcoidosis","authors":"Jong-Wook Shin, B. Choi, I. Park","doi":"10.1183/13993003.CONGRESS-2018.PA5218","DOIUrl":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA5218","url":null,"abstract":"","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123477443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}